供应商免费入驻

仪器信息网试剂标物生化试剂生物分子 VE-822

仪信通第 2 年

爱必信(上海)生物科技有限公司

认证：工商信息已核实

厂商展位

找不到产品？留下需求帮您找

一键询价

VE-822

价格：￥ 1125

品牌：爱必信

供货周期：一周

货号：abs813881

规格：>98%

CAS：1232416-25-9

一键咨询

获取电话

详细信息

详细信息

公告提醒：爱必信所有产品和服务仅用于科学研究，不用于临床应用及其他用途提供产品和服务（也不为任何个人提供产品和服务）!

抑制剂描述：

产品名称：VE-822

产品别名：见爱必信官网

英文别名：VE-822

靶点：ATM/ATR

CAS：1232416-25-9

纯度：>98%

外观：见爱必信官网

保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months.

描述：

VE-822是选择性ATR抑制剂，K_i< 0.2 nM，ATR选择性比高相关性的PI3K关联酶ATM/DNA-PK高了170倍。作为对XRT和gemcitabine的响应，VE-822（80 nM）减弱ATR信号传导途径，并降低肿瘤细胞存活率。在正常细胞中，VE-822（80 nM）减弱ATR信号通路强度，但并没有增强辐射和gemcitabine杀伤正常细胞的能力。与XRT中的MiaPaCa-2和PSN-1细胞相比，VE-822（80 nM）增加XRT引起的残余γH2AX和53BP1灶。

溶解性：DMSO ：34 mg/mL (73.3 mM)

体外研究：

VE-822 (80 nM) attenuates ATR signaling pathway and reduces survival in tumor cells in response to XRT and gemcitabine. VE-822 (80 nM) attenuates ATR signaling in normal cells without enhancing radiation and gemcitabine killing in normal cells. VE-822 (80 nM) increases XRT-induced residual γH2AX and 53BP1 foci compared with XRT in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) pre-treatment decreases Rad51 foci after XRT in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) alone increases the G1-phase-fraction in MiaPaCa-2 and PSN-1 cells. VE-822 (80 nM) abrogates XRT enriched G2/M-phase-fraction in MiaPaCa-2 and PSN-1 cells. VE-822 has little effect alone, while VE-822 (80 nM) combined with XRT and/or gemcitabine enhances early and late apoptosis in PSN-1 cells that is strongest in the triple combination. VE-822 increases tumor response to DNA damaging agents associated with blockade of pChk1 Ser345.

体内研究：VE-822 (60 mg/kg) inhibits phospho-Ser-345-Chk1 in mice bearing PSN-1 tumors after DNA-damaging agents. VE-822 (60 mg/kg) combined with XTR doubles the time for tumors to grow to 600 mm3 of XRT alone in mice bearing both PSN-1 and MiaPaCa-2 tumors. VE-822 (60 mg/kg) added to the combination of gemcitabine and XRT substantially prolongs the tumor growth delay compared with the Gem+XRT1 group n mice bearing both PSN-1 tumors. VE-822 (60 mg/kg) combined with XRT1 increases uptake in tumors by 44% compared with XRT1, suggesting that addition of VE-822 increased γH2AX phosphorylation and persistence of DNA damage caused by XRT.

产品信息订购：

产品货号	产品名称	规格	价格	大包装及货期
abs813881	VE-822	10mg	1125.00	立即咨询
abs813881	VE-822	50mg	3838.00	立即咨询
abs813881	VE-822	5mg	783.00	立即咨询
abs813881	VE-822	25mg	2310.00	立即咨询

产品更多信息请进入爱必信网站咨询

生化试剂 VE-822由爱必信(上海)生物科技有限公司为您提供，如想了解更多关于生物分子 VE-822的报价、规格、厂家等信息，欢迎来电或留言咨询。除供应VE-822外，爱必信(上海)生物科技有限公司还可为您提供：

推荐专场